J
9.04
-0.10 (-1.09%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Jade Biosciences, Inc. | 看涨 | - |
AIStockmoo 评分
2.0
| 分析师共识 | 3.0 |
| 内部交易活动 | 3.0 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.00 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.04% |
| 机构持股比例 | 33.40% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Versant Venture Management, Llc | 30 Jun 2025 | 1,525,820 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 28.00 (BTIG, 209.74%) | 购买 |
| 中 | 23.00 (154.43%) | |
| 低 | 18.00 (Wedbush, 99.12%) | 购买 |
| 平均值 | 23.00 (154.43%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 8.09 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 09 Oct 2025 | 28.00 (209.73%) | 购买 | 9.40 |
| Wedbush | 14 Aug 2025 | 18.00 (99.12%) | 购买 | 6.77 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| FAIRMOUNT FUNDS MANAGEMENT LLC | 9.14 | - | 1,333,126 | 12,184,772 |
| 累积净数量 | 1,333,126 | |||
| 累积净值 ($) | 12,184,772 | |||
| 累积平均购买 ($) | 9.14 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| FAIRMOUNT FUNDS MANAGEMENT LLC | 董事 | 06 Oct 2025 | 获得 (+) | 1,333,126 | 9.14 | 12,184,772 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合